Dr Jennifer King speaks to ecancer about a phase II trial of cabozantinib in relapsed refractory germ-cell tumours (GCT).

This trial evaluated cabozantinib, a multi-targeted tyrosine kinase inhibitor, in patients with relapsed or refractory germ cell tumours (GCT) who had progressed after multiple prior treatments.

Among 44 evaluable patients, the clinical benefit rate was 43.2 percent, driven primarily by durable stable disease, although no complete responses were observed.

Nearly half of patients showed measurable tumour shrinkage, and most experienced reductions in tumour markers.

Treatment was generally well tolerated, with mostly low-grade side effects and limited severe toxicity.

Dr King concludes by saying that these results suggest cabozantinib provides a meaningful non-chemotherapy option with disease control and a manageable safety profile in heavily pretreated GCT.